Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Make has participated in advisory boards, speaker bureaus, consultations, and multicenter clinical trials with funding from the National Heart, Lung, and Blood Institute; Abbott Laboratories; Astellas Pharma US, Inc; AstraZeneca; Boehringer Ingelheim GmbH; Dey Pharma LP; Forest Laboratories, Inc; GlaxoSmithKline plc; Merck & Co, Inc; MedImmune, LLC; Nabi Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals International GmbH; Pfizer, Inc; Philips Respironics; Sunovion Pharmaceuticals Inc; Sequel Pharmaceuticals, Inc; and Talecris Biotherapeutics. Dr Martinez has participated in advisory boards in COPD development for Actelion Pharmaceuticals Ltd; AstraZeneca; Bayer AG; BoomComm; Fb Communications; Forest Laboratories, Inc; Almirall, SA; GlaxoSmithKline plc; Ikaria, Inc; MedImmune LLC; Merck & Co, Inc; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals International GmbH; Pearl Therapeutics Inc; Pfizer, Inc; Hoffmann-La Roche Inc; Bayer Schering Pharma AG; and Talecris Biotherapeutics. He has been a member of steering committees for COPD studies sponsored by Actelion Pharmaceuticals, Inc; GlaxoSmithKline plc; Forest Laboratories, Inc; Mpex Pharmaceuticals, Inc; and Takeda Pharmaceuticals International GmbH. He has participated in Food and Drug Administration mock panels for Boehringer Ingelheim GmbH and Forest Laboratories, Inc. The University of Michigan received funds from Boehringer Ingelheim GmbH for a COPD study. Dr Martinez has served on speaker’s bureaus or in continuing medical education activities sponsored by the American Lung Association; Almirall, SA; Altana; AstraZeneca; Boehringer Ingelheim GmbH; CME Incite; ePocrates, Inc; Forest Laboratories, Inc; The France Foundation; GlaxoSmithKline plc; Med Ed, Inc; NACE International; Pfizer, Inc; Potomac Center for Medical Education; Prescott Pharmaceuticals; Sanofi-Aventis US LLC; Vox Medica, Inc; WebMD, LLC; and UpToDate, Inc. He has received royalties from Associates in Medical Marketing and Castle Connolly Medical Ltd. Dr Sciurba has received research funds from the National Institutes of Health; GlaxoSmithKline plc; Pfizer, Inc; Boehringer Ingelheim GmbH; and Forest Laboratories, Inc. He has received consulting funds from GlaxoSmithKline plc; AstraZeneca plc; and PnuemRX. Drs Chandra, Wise, Kulkarni, Benzo, Criner, Ries, and Reilly and Mr Slivka have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.